Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

From the authors

S. Ewig, M. A. Woodhead
European Respiratory Journal 2006 28: 254-255; DOI: 10.1183/09031936.06.00047806
S. Ewig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. A. Woodhead
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

We welcome the contribution from K. Challen and co-workers concerning their pandemic medical early warning score (PMEWS) compared with CURB-65 (confusion, urea >7 mmol·L-1, respiratory rate ≥30·min-1, low blood pressure, and aged ≥65 yrs) and CRB-65 (confusion, respiratory rate ≥30·min-1, low blood pressure, and aged ≥65 yrs) as measures to determine hospital and intensive care unit admission for patients with lower respiratory tract infection (LRTI) and community-acquired pneumonia (CAP), but would urge caution before deciding which test to use in either CAP or pandemic influenza.

CURB-65 and CRB-65 have been developed for the assessment, at hospital admission, of patients with CAP and have now been validated in widely different populations 1. Draft UK guidelines for the clinical management of pandemic influenza (www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID = 4121753&chk = ZXKxus) have used these scores as examples of how a severity scoring tool might be used in the light of this evidence base. However, neither the CURB scores nor PMEWS have actually been tested in patients with seasonal, let alone pandemic, influenza where their operational characteristics may be different.

Other important issues are that CURB scores have been assessed in large patient populations compared with the 195 LRTI and 99 CAP patients described by K. Challen and co-workers. Important information is omitted by K. Challen and co-workers including: the definition of LRTI used; the proportion of LRTI patients admitted to hospital; and how many patients had missing variables. Without scrutiny of such information, we would not agree with these authors that they have shown that PMEWS can provide a more accurate assessment of need for hospital admission.

Importantly, K. Challen and co-workers fail to mention that PMEWS is a graded score for each parameter, rather than the categorical scores used in CURB, making PMEWS inherently more complex to use, especially outside the hospital. In addition, CRB-65 can be calculated without any laboratory or oximetric results.

The medical early warning score has the potential advantages of not being disease specific, and familiarity of use in some UK hospitals at least, for the assessment of patients already admitted to hospital. However, we know of no studies reporting its use as a tool for the hospital admission decision.

More detailed and prospective assessment will be required before pandemic medical early warning scores can be recommended in preference to a score validated in a number of populations and now adopted in a number of international community-acquired pneumonia guidelines (www.brit-thoracic.org/guidelines) 2–4.

    • © ERS Journals Ltd

    References

    1. ↵
      Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377–382.
      OpenUrlAbstract/FREE Full Text
    2. ↵
      Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138–1180.
      OpenUrlAbstract/FREE Full Text
    3. Hedlund J, Stralin K, Ortqvist A, Holmberg H. Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults. Scand J Infect Dis 2005;37:791–805.
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      Schouten JA, Prins JM, Bonten M, et al. [Optimizing the antibiotics policy in The Netherlands. VIII. Revised SWAB guidelines for antimicrobial therapy in adults with community-acquired pneumonia]. Ned Tijdschr Geneeskd 2005;149:2495–2500.
      OpenUrlPubMed
    PreviousNext
    Back to top
    View this article with LENS
    Vol 28 Issue 1 Table of Contents
    European Respiratory Journal: 28 (1)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    From the authors
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    From the authors
    S. Ewig, M. A. Woodhead
    European Respiratory Journal Jul 2006, 28 (1) 254-255; DOI: 10.1183/09031936.06.00047806

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    From the authors
    S. Ewig, M. A. Woodhead
    European Respiratory Journal Jul 2006, 28 (1) 254-255; DOI: 10.1183/09031936.06.00047806
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
    • Optimised surveillance of bronchial dysplasia in risky population
    • Reply: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society